Core Viewpoint - Iradimed has achieved significant financial growth, setting a new all-time high in revenue for the 18th consecutive quarter, with both revenue and net income increasing at double-digit rates, leading to a nearly 10% rise in stock price on the announcement day [1]. Financial Performance - In Q4 2025, Iradimed reported revenue of $22.7 million, a 17% increase compared to Q4 2024. Net income rose 23% to just under $7 million, equating to $0.54 per share [2]. - The company exceeded consensus analyst estimates for earnings per share, which was projected at $0.48 [3]. Product Development - Iradimed's growth was bolstered by the launch of a new product, the 3870 intravenous infusion pump, which began shipping during the quarter [4]. Dividend Announcement - The company announced an increase in its quarterly dividend from $0.17 to $0.20 per share, effective March 6 for investors of record as of February 23 [5]. Future Guidance - For the full year 2026, Iradimed projects revenue between $91 million and $96 million, with non-GAAP net income expected to be between $2.06 and $2.21 per share, both significantly higher than the 2024 figures of $73 million in revenue and $1.66 per share adjusted net profit [6]. Market Position - Iradimed is positioned as a strong player in the niche medical devices segment, particularly in MRI-compatible equipment, indicating a continued growth trajectory [7].

Core Viewpoint - Edwards Lifesciences has forecasted 2026 profit above estimates, driven by strong demand for its artificial heart valves and other medical devices, resulting in a 3% increase in shares during after-hours trading [1] Group 1 - The company anticipates robust demand for its artificial heart valves and medical devices [1] - The positive forecast has led to a rise in the company's stock price by 3% in after-hours trading [1]

Core Viewpoint - Ocumetics Technology Corp. has entered into a forbearance agreement with debentureholders, allowing them to defer payment on secured convertible debentures until June 19, 2027, despite the original maturity date [1]. Group 1: Forbearance Agreement - The forbearance agreement involves debentures with a total face value of up to $4,000,000, bearing an interest rate of 18% per annum, compounded annually [2]. - The Corporation can prepay the debentures with a 90-day prior written notice without incurring penalties [2]. - The principal amount of the debentures is convertible into common shares at a price of $0.32 per share until the maturity date [3]. Group 2: Warrants Issuance - In exchange for the forbearance, Ocumetics issued 9,153,277 share purchase warrants to debentureholders, allowing them to purchase common shares at an exercise price of $0.58 until June 19, 2027 [4]. - The warrants are classified as bonus warrants under TSX Venture Exchange Policy 5.1, with specific terms regarding repayment or conversion of the debentures [4]. Group 3: Offering Details - The previously announced offering under the listed issuer financing has terminated, with 1,706,383 units sold at a price of $0.60 per unit, generating approximately $1,023,830 in gross proceeds [5]. - Each unit consists of one common share and one common share purchase warrant, with the warrant allowing purchase of an additional common share at $0.75 until December 30, 2028 [5]. Group 4: Company Overview - Ocumetics Technology Corp. is a Canadian research and product development company focused on advanced vision correction solutions aimed at enhancing patients' quality of life [6]. - The company is in the early feasibility study phase of developing a revolutionary intraocular lens designed to eliminate the need for corrective lenses, allowing natural focus adjustment [8].

Core Insights - Edwards Lifesciences reported a 13.3% increase in Q4 sales, reaching $1.57 billion, with constant currency sales growing by 11.6% [1] - The company's TAVR (Transcatheter Aortic Valve Replacement) sales grew by 12.0% to $1.16 billion, with constant currency sales increasing by 10.6% [1] - TMTT (Transcatheter Mitral and Tricuspid Therapies) sales surged over 40% to $156 million, driven by repair and replacement therapies [1] - The Q4 earnings per share (EPS) was reported at $0.11, while the adjusted EPS stood at $0.58 [1] - For the full year 2025, sales grew by 11.5%, with constant currency sales increasing by 10.7% [1]

TUCSON, Ariz., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Dr. Andre Simon, Vice President of Clinical Affairs will attend and present data on the fully implantable Emperor Total Artificial Heart (TAH) at the upcoming 19th EUMS (European Mechanical Circulatory Support Summit) & 11th Intern ...

Enovis Corporation (NYSE:ENOV) is included in our list of the 14 oversold value stocks to invest in right now. Evercore ISI Bullish on Enovis (ENOV) Despite Weak Share Price Momentum Pixabay/Public domain Enovis Corporation (NYSE:ENOV) underwent a challenging period in 2025 amid macro headwinds. With the stock down 50% over the past year, the shares ended-up hitting their 52-week low on January 29, 2026, closing at $21.00. Amid weak investor momentum, Enovis Corporation (NYSE:ENOV) drew attention from ...

on LinkedIn][Scott+Scott on X]Get RSS Feed## Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation Into Hub Group, Inc. (NASDAQ: HUBG)NEW YORK--([BUSINESS WIRE])--Scott+Scott Attorneys at Law LLP ("Scott+Scott†), a shareholder and consumer rights litigation firm, is investigating whether Hub Group, Inc. ("Hub Group†or the "Company†) (NASDAQ: HUBG) or certain of its officers and directors issued misleading and false statements and/or failed to disclose information material to investors i ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased Tandem Diabetes securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to Tandem Diabetes [2]. Group 2: Company Incident and Stock Impact - On August 7, 2025, Tandem Diabetes issued a press release regarding a voluntary medical device correction for select t:slim X2 insulin pumps, which stated a potential speaker-related issue could lead to insulin delivery discontinuation [3]. - Following this announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Financial Performance - The company reported sales of $5.25 billion, slightly above the consensus of $5.15 billion [1] - For the second quarter, the company expects adjusted earnings of $2.72 to $2.82 per share [4] Guidance - Becton Dickinson lowers fiscal 2026 adjusted earnings guidance from $14.75-$15.05 per share to $12.35-$12.65 per share compared to the consensus of $14.72 [2] - Analyst Shagun Singh noted that despite the lower-than-expected fiscal second quarter guide, the fiscal 2026 guide was kept intact as business trends are playing out as expected [4] Analyst Ratings and Price Targets - RBC Capital Markets lowered its price forecast for Becton Dickinson from $210 to $172, citing FY26 as a transition year and reflecting the Waters deal dynamics [3] - Wells Fargo maintains Becton Dickinson with an Equal-Weight and lowers the price target from $184 to $157 [6] - Piper Sandler reiterates BD with a Neutral and lowers the price target from $205 to $170 [6] - Citigroup maintains BD with a Buy and lowers the price target from $233 to $232 [6] Business Outlook - RBC models organic revenue growth of 2.5% in fiscal 2026 and 2.4% in fiscal 2027, with EPS growth of 6.0% in fiscal 2026 and 6.9% in fiscal 2027 [3] - Approximately 90% of the company's business is currently delivering mid-single digits growth [5] - The company's management is focused on tuck-in M&A, with a robust pipeline aimed at accretive M&A [5]

Core Insights - GE HealthCare Technologies Inc. (GEHC) has launched ReadyFix, a remote fleet management solution designed to enhance medical device uptime and operational efficiency in healthcare systems [1][8] - The solution integrates with MAC VU360 ECG workstations, providing high-quality ECG measurements and real-time data access for remote diagnostics and maintenance [1][4] Product Launch and Features - ReadyFix aims to simplify maintenance and operations of connected medical devices, allowing healthcare teams to focus on cardiac patient care [2][4] - The platform supports centralized management of device complexity, enabling standardized clinical configurations and facilitating proactive maintenance through real-time diagnostics [9][10] Market Context and Trends - The fleet management market is projected to reach $32.29 billion by 2026, with a CAGR of 10% through 2035, driven by the growth of connected medical devices and operational efficiency needs [13] - The increasing complexity of device management is highlighted by the fact that hospitals may have 10 to 15 connected devices per bed, leading to higher maintenance demands [10][11] Financial Performance and Stock Movement - Following the ReadyFix announcement, GEHC shares fell by 1.9%, although the company has seen an 8.3% increase over the past six months, contrasting with an 11.3% decline in the industry [3] - GEHC currently holds a market capitalization of $36.76 billion [6] Workforce Challenges - A significant portion of biomedical engineers report heavy workloads, with projections indicating over 7,300 annual job openings for biomedical equipment technicians in the next decade, while only about 400 graduates are produced annually [11] - ReadyFix is positioned to help hospitals maintain high reliability standards despite workforce constraints [11][12]